We are live on ! Find out more
REVB icon

Revelation Biosciences

7 hedge funds and large institutions have $1.05M invested in Revelation Biosciences in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

250% more funds holding

Funds holding: 27 (+5)

145% more capital invested

Capital invested by funds: $427K → $1.05M (+$621K)

0.02% more ownership

Funds ownership: 0%0.02% (+0.02%)

Holders
7
Holders Change
+5
Holders Change %
+250%
% of All Funds
0.11%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
Reduced
Closed
1
Calls
Puts
Net Calls
Net Calls Change

REVB Hedge Fund Activity: Q1 2023 in Review

7 of the 6,278 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences (REVB) for Q1 2023, worth a combined $1.05M — up 145% from $427K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new REVB positions and 1 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $999K. The largest seller was State Street, exiting entirely with an estimated $20.9K sold.

  • 7 institutional investors held Revelation Biosciences (REVB) as of Q1 2023, up from 2 in Q4 2022.
  • Funds reported $1.05M of Revelation Biosciences stock for Q1 2023, up 145% quarter-over-quarter.
  • 6 funds opened new Revelation Biosciences positions in Q1 2023 and 1 closed out, a net change of +5 holders.
  • The largest Revelation Biosciences buyer in Q1 2023 was Anson Funds Management, an estimated $999K added.
  • The largest Revelation Biosciences seller in Q1 2023 was State Street, an estimated $20.9K sold.

Based on aggregated 13F filings for Q1 2023.